201 related articles for article (PubMed ID: 38344806)
1. Parkinson's disease psychosis management: an evidence based, experience informed, pragmatic approach.
Friedman JH
Expert Opin Pharmacother; 2024 Feb; 25(2):149-156. PubMed ID: 38344806
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological interventions for psychosis in Parkinson's disease patients.
Friedman JH
Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
[TBL] [Abstract][Full Text] [Related]
3. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
[TBL] [Abstract][Full Text] [Related]
4. Management of Parkinson's Disease Psychosis.
Elsibai H; Kualleny M; Fandy TE
Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841
[No Abstract] [Full Text] [Related]
5. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Majlath Z; Obal I; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
[TBL] [Abstract][Full Text] [Related]
6. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
Isaacson SH; Citrome L
Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847
[TBL] [Abstract][Full Text] [Related]
7. Current Understanding of Psychosis in Parkinson's Disease.
Ojo OO; Fernandez HH
Curr Psychiatry Rep; 2016 Oct; 18(10):97. PubMed ID: 27629356
[TBL] [Abstract][Full Text] [Related]
8. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
Zahodne LB; Fernandez HH
Drugs Aging; 2008; 25(8):665-82. PubMed ID: 18665659
[TBL] [Abstract][Full Text] [Related]
10. Treatment of psychosis in Parkinson's disease: safety considerations.
Fernandez HH; Trieschmann ME; Friedman JH
Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
[TBL] [Abstract][Full Text] [Related]
11. Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
Samudra N; Patel N; Womack KB; Khemani P; Chitnis S
Drugs Aging; 2016 Dec; 33(12):855-863. PubMed ID: 27830568
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
[TBL] [Abstract][Full Text] [Related]
13. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
[No Abstract] [Full Text] [Related]
15. Atypical antipsychotic drugs in the treatment of Parkinson's disease.
Friedman JH
J Pharm Pract; 2011 Dec; 24(6):534-40. PubMed ID: 22095576
[TBL] [Abstract][Full Text] [Related]
16. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
Duits JH; Ongering MS; Martens HJM; Schulte PFJ
Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
[TBL] [Abstract][Full Text] [Related]
17. Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis.
Srisurapanont M; Suradom C; Suttajit S; Kongsaengdao S; Maneeton B
Gen Hosp Psychiatry; 2024; 87():124-133. PubMed ID: 38412585
[TBL] [Abstract][Full Text] [Related]
18. Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.
Broadstock M; Ballard C; Corbett A
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):779-86. PubMed ID: 25301532
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease psychosis 2010: a review article.
Friedman JH
Parkinsonism Relat Disord; 2010 Nov; 16(9):553-60. PubMed ID: 20538500
[TBL] [Abstract][Full Text] [Related]
20. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
